📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
1 articles
AVG GRADE
HIGH
score: 0.50
SENTIMENT
BULLISH
TOTAL VIEWS
13
IVBXF Latest News & AI Sentiment Analysis
1 articles · Grade: HIGH · Real-time AI-graded coverage
RECENT COVERAGE · 3 ARTICLES
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
Spero Therapeutics and Innovent Biologics have entered an exclusive licensing agreement for SP001 (IBI355), a Phase 2-ready anti-CD40L...
Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
Eli Lilly and Innovent Biologics have formalized a commercialization partnership for Verzenios® (abemaciclib), a CDK4&6 inhibitor,...
Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma
Innovent Biologics has initiated dosing in a pivotal Phase 3 trial for IBI3003, a tri-specific antibody targeting multiple myeloma. This...
RELATED TICKERS
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice